Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 9, 2013, Pages 1520-1528

  FitzGerald, Liesel M ^a   Kumar, Akash ^b   Boyle, Evan A ^b   Zhang, Yuzheng ^a   McIntosh, Laura M ^a   Kolb, Suzanne ^a   Stott Miller, Marni ^a   Smith, Tiffany ^d   Karyadi, Danielle M ^d   Ostrander, Elaine A ^d   Hsu, Li ^a   Shendure, Jay ^b   Stanford, Janet L ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b ROSS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; EXOME; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PHENOTYPE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUTATION, MISSENSE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84884150338     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0345     Document Type: Article

References (51)

1. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343: 78-85.
2. Goh CL, Schumacher FR, Easton D, Muir K, Henderson B, Kote-Jarai Z, et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 2012;271: 353-65.
3. Eeles R, Al Olama AA, Benlloch S, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45: 385-91.
4. Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 2000;67: 1367-75.
5. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJICPCG. Where are the prostate cancer genes?-A summary of eight genome wide searches. Prostate 2003;57: 261-9.
6. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13:R103-R21.
7. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72: 1-12.
8. Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007;97: 826-31.
9. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230-4.
10. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk.NEngl J Med 2012;366: 141-9.
11. Xu J, Lange EM, Lu L, Zheng SL,WangZ, Thibodeau SN, et al.HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2013;132: 5-14.
12. Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A, et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst 2012;104: 1260-2.
13. Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol 2012.[Epub ahead of print].
14. Stott-Miller M, KaryadiDM, King T,KwonEM, Kolb S, Stanford JL, et al. HOXB13 mutations in a population-based, case control study of prostate cancer. Prostate 2013;73: 634-41.
15. Stanford JL, FitzGerald LM, McDonnell SK, Carlson EE, McIntosh LM, Deutsch K, et al. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet 2009;18: 1839-48.
16. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8: 881-6.
17. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008;168: 250-60.
18. Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics (Oxford, England) 2009;25: 1754-60.
19. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20: 1297-303.
20. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009; 25: 2078-9.
21. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009;461: 272-6.
22. O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 2011;43: 585-9.
23. Cooper GM, Stone EA, Asimenos G, Green ED, Batzoglou S, Sidow A. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res 2005;15: 901-13.
24. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001;10: 591-7.
25. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31: 3812-4.
26. Grantham R. Amino acid difference formula to help explain protein evolution. Science 1974;185: 862-4.
27. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. Genome Res 2009;19: 1553-61.
28. Henikoff S, Henikoff JG. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 1992;89: 10915-19.
29. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res 2002; 12: 996-1006.
30. Turner EH, Lee C, NgSB, Nickerson DA, Shendure J. Massively parallel exon capture and library-free resequencing across 16 genomes. Nat Methods 2009;6: 315-6.
31. O'Roak BJ, Vives L, Fu W, Egertson J, Stanaway I, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012;338: 1619-22.
32. Allen-Brady K, Wong J, Camp NJ. PedGenie: an analysis approach for genetic association testing in extended pedigrees and genealogies of arbitrary size. BMC Bioinformatics 2006;7: 209.
33. Breslow NE, Day NE. Statistical methods in cancer research, volume 1- the analysis of case-control studies. Lyon, France: International Agency for Research on Cancer; 1980.
34. Grasso CS,WuYM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487: 239-43.
35. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007;12: 559-71.
36. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004;101: 6062-67.
37. Abeler-Dorner L, Swamy M, Williams G, Hayday AC, Bas A. Butyrophilins: an emergine family of immune regulators. Trends Immunol 2012;33: 34-41.
38. Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, et al. BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J Immunol 2007;178: 1523-33.
39. Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol 2006;176: 7354-60.
40. Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005;37: 357-64.
41. Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC, Group AR. The BTNL2 gene and sarcoidosis susceptibility in African Americans and whites. Am J Hum Genet 2005;77: 491-9.
42. Mitsunaga S, Hosomichi K, Okudaira Y, Nakaoka H, Kunii N, Suzuki Y, et al. Exome sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2. J Human Genet 2013;58: 210-5.
43. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008;40: 1319-23.
44. Silverberg MS, Cho JH, Rioux JD, McGovern DP,WuJ, Annese V, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 2009;41: 216-20.
45. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7.
46. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172:S6-11.
47. ENCODE. Available from: http://genome.ucsc.edu/ENCODE/.
48. Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith Jr. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2012;21: 1348-53.
49. Genome Variation Server. Available from: http://pga.gs.washington. edu/.
50. ClinSeq Project. Available from: http://www.genome.gov/20519355.
51. 1000 Genomes Project, 2008-2011. Available from: http://www. 1000genomes.org/.